Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices 49215 

TABLE 1—Continued 

Application No. Drug Applicant 

ANDA 085720 ........ Meprobamate Tablets USP, 200 mg ........................................................ Do. 

ANDA 085721 ........ Meprobamate Tablets USP, 400 mg ........................................................ Do. 

ANDA 085778 ........ Hydroxyzine HCl Injection USP, 25 mg/mL .............................................. Do. 

ANDA 086096 ........ Chlorpheniramine Maleate Injection USP, 10 mg/mL ............................... Do. 

ANDA 086189 ........ Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg ............................... Do. 

ANDA 086598 ........ Nandrolone Decanoate Injection USP, 100 mg/mL .................................. Do. 

ANDA 086795 ........ Chlorothiazide Tablets USP, 250 mg ........................................................ Do. 

ANDA 087183 ........ Ergoloid Mesylates Sublingual Tablets USP, 1 mg .................................. Do. 

ANDA 087296 ........ Chlorthalidone Tablets USP, 25 mg ......................................................... Do. 

ANDA 087521 ........ Chlorthalidone Tablets USP, 50 mg ......................................................... Do. 

ANDA 087772 ........ Prednisone Tablets USP, 50 mg .............................................................. Do. 

ANDA 087979 ........ Chloroquine Phosphate Tablets USP, EQ 150 mg base ......................... Do. 

ANDA 088030 ........ Chloroquine Phosphate Tablets USP, EQ 300 mg base ......................... Do. 

ANDA 089042 ........ Procainamide HCl Extended-Release Tablets USP, 750 mg ................... Do. 

Therefore, approval of the 

applications listed in table 1, and all 

amendments and supplements thereto, 

is hereby withdrawn as of November 24, 

2017. Introduction or delivery for 

introduction into interstate commerce of 

products without approved new drug 

applications violates section 301(a) and 

(d) of the Federal Food, Drug, and 

Cosmetic Act (21 U.S.C. 331(a) and (d)). 

Drug products that are listed in table 1 

that are in inventory on the date that 

this notice becomes effective (see the 

DATES section) may continue to be 

dispensed until the inventories have 

been depleted or the drug products have 

reached their expiration dates or 

otherwise become violative, whichever 

occurs first. 

Dated: October 18, 2017. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2017–23046 Filed 10–23–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID SBIR Phase II 

Clinical Trial Implementation Cooperative 

Agreement (U44). 

Date: November 17, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Vasundhara Varthakavi, 

Ph.D., DVM, Scientific Review Officer, 

Scientific Review Program, Division of 

Extramural Activities, Room 3E70, National 

Institutes of Health, NIAID, 5601 Fishers 

Lane, MSC 9823, Bethesda, MD 20892–9823, 

(240) 669–5020, varthakaviv@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 18, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22967 Filed 10–23–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

International Research Ethics Training. 

Date: November 16, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Karin F. Helmers, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3148, 

MSC 7770, Bethesda, MD 20892, (301) 254– 

9975, helmersk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR16–121 

Early-Stage Preclinical Validation of 

Therapeutic Leads for Diseases of Interest to 

the NIDDK (R01). 

Date: November 16, 2017. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Raul Rojas, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6185, 

Bethesda, MD 20892, (301) 451–6319, rojasr@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Macromolecular Structure and 

Function. 

Date: November 20, 2017. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: C-L Albert Wang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
49216 Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices 

Health, 6701 Rockledge Drive, Room 4146, 

MSC 7806, Bethesda, MD 20892, 301–435– 

1016, wangca@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 18, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22966 Filed 10–23–17; 8:45 am] 

BILLING CODE 4140–01–P 

ADVISORY COUNCIL ON HISTORIC 

PRESERVATION 

Notice of Advisory Council on Historic 

Preservation Quarterly Business 

Meeting 

AGENCY: Advisory Council on Historic 

Preservation. 

ACTION: Notice of Advisory Council on 

Historic Preservation Quarterly Business 

Meeting. 

SUMMARY: Notice is hereby given that 

the Advisory Council on Historic 

Preservation (ACHP) will hold its next 

quarterly meeting on Thursday, 

November 9 2017. The meeting will be 

held in Room SR325 at the Russell 

Senate Office Building at Constitution 

and Delaware Avenues NE., 

Washington, DC, starting at 8:30 a.m. 

DATES: The quarterly meeting will take 

place on Thursday, November 9 2017, 

starting at 8:30 a.m. 

ADDRESSES: The meeting will be held in 

Room SR325 at the Russell Senate 

Office Building at Constitution and 

Delaware Avenues NE., Washington, 

DC. 

FOR FURTHER INFORMATION CONTACT: 

Cindy Bienvenue, 202–517–0202, 

cbienvenue@achp.gov. 

SUPPLEMENTARY INFORMATION: The 

Advisory Council on Historic 

Preservation (ACHP) is an independent 

federal agency that promotes the 

preservation, enhancement, and 

sustainable use of our nation’s diverse 

historic resources, and advises the 

President and the Congress on national 

historic preservation policy. The goal of 

the National Historic Preservation Act 

(NHPA), which established the ACHP in 

1966, is to have federal agencies act as 

responsible stewards of our nation’s 

resources when their actions affect 

historic properties. The ACHP is the 

only entity with the legal responsibility 

to encourage federal agencies to factor 

historic preservation into their decision 

making. For more information on the 

ACHP, please visit our Web site at 

www.achp.gov. 

The agenda for the upcoming 

quarterly meeting of the ACHP is the 

following: 

I. Chairman’s Welcome 

II. Section 106 Issues 

A. Administration Infrastructure 

Initiatives 

B. ACHP Response to Recent Natural 

Disasters 

C. Proposed Exemption Regarding 

Railroad and Rail Transit Rights of 

Way 

D. ACHP Report to the President 

Pursuant to Executive Order 13287 

E. Development of an Online Section 

106 Forum 

F. ACHP Regulatory Review Progress 

III. Historic Preservation Policy and 

Programs 

A. Policy Statement on 

Commemorative Works 

B. ACHP Recommendations for the 

Future of the National Historic 

Preservation Program 

C. Historic Preservation Legislation in 

the 115th Congress 

D. ACHP Speakers’ Bureau Proposal 

E. ACHP/HUD Historic Preservation 

Award Follow Up 

IV. New Business 

V. Adjourn 

The meetings of the ACHP are open 

to the public. If you need special 

accommodations due to a disability, 

please contact Cindy Bienvenue, 202– 

517–0202 or cbienvenue@achp.gov, at 

least seven (7) days prior to the meeting. 

Authority: 54 U.S.C. 304102. 

Dated: October 18, 2017. 

Javier E. Marques, 

General Counsel. 

[FR Doc. 2017–23000 Filed 10–23–17; 8:45 am] 

BILLING CODE 4310–K6–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2017–0158] 

Collection of Information Under 

Review by Office of Management and 

Budget; OMB Control Number: 1625– 

0017 

AGENCY: Coast Guard, DHS. 

ACTION: Thirty-day notice requesting 

comments. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995 the 

U.S. Coast Guard is forwarding an 

Information Collection Request (ICR), 

abstracted below, to the Office of 

Management and Budget (OMB), Office 

of Information and Regulatory Affairs 

(OIRA), requesting approval for 

reinstatement, without change, of the 

following collection of information: 

1625–0017, Various International 

Agreement Safety Certificates and 

Documents. Our ICR describe the 

information we seek to collect from the 

public. Review and comments by OIRA 

ensure we only impose paperwork 

burdens commensurate with our 

performance of duties. 

DATES: Comments must reach the Coast 

Guard and OIRA on or before November 

24, 2017. 

ADDRESSES: You may submit comments 

identified by Coast Guard docket 

number [USCG–2017–0158] to the Coast 

Guard using the Federal eRulemaking 

Portal at http://www.regulations.gov. 

Alternatively, you may submit 

comments to OIRA using one of the 

following means: 

(1) Email: dhsdeskofficer@

omb.eop.gov. 

(2) Mail: OIRA, 725 17th Street NW., 

Washington, DC 20503, attention Desk 

Officer for the Coast Guard. 

A copy of the ICR is available through 

the docket on the Internet at http://

www.regulations.gov. Additionally, 

copies are available from: Commandant 

(CG–612), ATTN: Paperwork Reduction 

Act Manager, U.S. Coast Guard, 2703 

Martin Luther King Jr. Ave. SE., Stop 

7710, Washington, DC 20593–7710. 

FOR FURTHER INFORMATION CONTACT: 

Contact Mr. Anthony Smith, Office of 

Information Management, telephone 

202–475–3532, or fax 202–372–8405, for 

questions on these documents. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

This Notice relies on the authority of 

the Paperwork Reduction Act of 1995; 

44 U.S.C. Chapter 35, as amended. An 

ICR is an application to OIRA seeking 

the approval, extension, or renewal of a 

Coast Guard collection of information 

(Collection). The ICR contains 

information describing the Collection’s 

purpose, the Collection’s likely burden 

on the affected public, an explanation of 

the necessity of the Collection, and 

other important information describing 

the Collection. There is one ICR for each 

Collection. The Coast Guard invites 

comments on whether this ICR should 

be granted based on the Collection being 

necessary for the proper performance of 

Departmental functions. In particular, 

the Coast Guard would appreciate 

comments addressing: (1) The practical 

utility of the Collection, (2) the accuracy 


asabaliauskas on DSKBBXCHB2PROD with NOTICES